Comment on: Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma

ESMO Open. 2024 Apr;9(4):102973. doi: 10.1016/j.esmoop.2024.102973. Epub 2024 Mar 19.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adenocarcinoma* / pathology
  • Esophageal Neoplasms / pathology
  • Esophagogastric Junction* / pathology
  • Humans
  • Incidence
  • Neoplasm Recurrence, Local* / epidemiology
  • Receptor, ErbB-2* / metabolism
  • Stomach Neoplasms* / pathology

Substances

  • Receptor, ErbB-2
  • ERBB2 protein, human